PSORİYAZİS VULGARİSİN ŞİDDETİ, VÜCUT KİTLE İNDEKSİ VE BEL ÇEVRESİ ARASINDAKİ İLİŞKİNİN DEĞERLENDİRİLMESİ

Efsun Tanacan; Nermin Karaosmanoğlu; Engin Karaaslan; Hatice Meral Ekşioğlu

Araştırma Makalesi

PSORİYAZİS VULGARİSİN ŞİDDETİ, VÜCUT KİTLE İNDEKSİ VE BEL ÇEVRESİ ARASINDAKİ İLİŞKİNİN DEĞERLENDİRİLMESİ

Yıl 2018, Cilt: 51 Sayı: 2, 150 - 153, 29.08.2018

Efsun Tanacan Nermin Karaosmanoğlu Engin Karaaslan Hatice Meral Ekşioğlu

Öz

AMAÇ: Bu
çalışmanın amacı psoriyazis
vulgarisin şiddeti ile vücut kitle indeksi (VKİ) ve bel çevresi arasındaki
ilişkinin değerlendirilmesidir.

GEREÇ VE YÖNTEMLER: Bu çalışmaya Sağlık Bilimleri Üniversitesi Ankara Eğitim ve Araştırma
Hastanesi Dermatoloji Kliniği’nde psoriyazis vulgaris tanısı alan toplam 75 hasta
dahil edildi. Hastalara çalışma ile ilgili bilgi verildi ve onamları alındı. Psoriyazis
vulgaris hastalığının şiddeti Psoriasis alan ve şiddet indeksi (PAŞİ)
kullanılarak belirlendi. Hastaların yaşı, VKİ ve PAŞİ değerleri kaydedildi. Psoriyazis
şiddeti ile VKİ ve bel çevresi arasındaki ilişki karşılaştırıldı.

BULGULAR: Çalışmaya 47’si erkek (62.6%) ve 28’i kadın
(37.4%) toplam 75 hasta dahil edildi. Hastaların yaş ortalaması 38.8±16.5 idi.
Ortalama bel çevresi, PAŞİ ve VKİ değerleri sırasıyla, 92.60±20.8, 15.3±11.8 ve
26.5±6.1 olarak bulundu. PAŞİ ile VKİ arasında istatistiksel olarak anlamlı bir
ilişki mevcut değilken; bel çevresi arttıkça hastalık şiddetinin de (PAŞİ) arttığı
tespit edildi (p=0.027).

SONUÇ: Bu
çalışmada, PAŞİ ile VKİ arasında anlamlı bir ilişki saptanmazken, psoriyazis
vulgaris hastalık şiddetinin bel çevresindeki artış ile doğru orantılı olarak
arttığı gösterilmiştir.

Anahtar Kelimeler

Psoriyazis, vücut kitle indeksi, bel çevresi

Kaynakça

1. Christophers E. Psoriasis− epidemiology and clinical spectrum. Clin Exp Dermatol. 2001 Jun;26(4):314-20.
2. Johnson MAN, Armstrong AW. Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol. 2013 Apr;44(2):166-72.
3. Di Meglio P, Nestle F.O. (2017) Immunopathogenesis of Psoriasis. In: Gaspari A., Tyring S., Kaplan D. (eds) Clinical and Basic Immunodermatology. Springer, Cham.
4. Mattei P, Corey K, Kimball A. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7.
5. Atakan N, Doğan S. Psoriazis Sistemik Bir Hastalık mıdır? Turk J Dermatol 2012; 6: 119-22.
6. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924-30.
7. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009 Nov;129(11):2604-12.
8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41.
9. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study. Br J Dermatol. 2007 Jul;157(1):68-73.
10. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009 Apr;145(4):379-82.
11. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007 Aug 13-27;167(15):1670-5.
12. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010 Dec;63(6):1058-69.
13. Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011 Oct;159(4):577-83.
14. Armstrong A, Harskamp C, Armstrong E. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2:e54.
15. McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR. The skinny on psoriasis and obesity. Arch Dermatol. 2005 Dec;141(12):1601-2.
16. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995 Jun;32(6):982-6.
17. Hamminga E, van der Lely A-J, Neumann H, Thio H. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768-73.
18. Ahmed M, Gaffen SL. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 2010 Dec;21(6):449-53.
19. Davidovici BB, Sattar N, Jörg PC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785-96.
20. Alexandroff A, Pauriah M, Camp R, Lang C, Struthers A, Armstrong D. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009 Jul;161(1):1-7.

Yıl 2018, Cilt: 51 Sayı: 2, 150 - 153, 29.08.2018

Efsun Tanacan Nermin Karaosmanoğlu Engin Karaaslan Hatice Meral Ekşioğlu

Öz

Kaynakça

1. Christophers E. Psoriasis− epidemiology and clinical spectrum. Clin Exp Dermatol. 2001 Jun;26(4):314-20.
2. Johnson MAN, Armstrong AW. Clinical and histologic diagnostic guidelines for psoriasis: a critical review. Clin Rev Allergy Immunol. 2013 Apr;44(2):166-72.
3. Di Meglio P, Nestle F.O. (2017) Immunopathogenesis of Psoriasis. In: Gaspari A., Tyring S., Kaplan D. (eds) Clinical and Basic Immunodermatology. Springer, Cham.
4. Mattei P, Corey K, Kimball A. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7.
5. Atakan N, Doğan S. Psoriazis Sistemik Bir Hastalık mıdır? Turk J Dermatol 2012; 6: 119-22.
6. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924-30.
7. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009 Nov;129(11):2604-12.
8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41.
9. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study. Br J Dermatol. 2007 Jul;157(1):68-73.
10. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009 Apr;145(4):379-82.
11. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med. 2007 Aug 13-27;167(15):1670-5.
12. Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010 Dec;63(6):1058-69.
13. Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011 Oct;159(4):577-83.
14. Armstrong A, Harskamp C, Armstrong E. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2:e54.
15. McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR. The skinny on psoriasis and obesity. Arch Dermatol. 2005 Dec;141(12):1601-2.
16. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995 Jun;32(6):982-6.
17. Hamminga E, van der Lely A-J, Neumann H, Thio H. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768-73.
18. Ahmed M, Gaffen SL. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 2010 Dec;21(6):449-53.
19. Davidovici BB, Sattar N, Jörg PC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010 Jul;130(7):1785-96.
20. Alexandroff A, Pauriah M, Camp R, Lang C, Struthers A, Armstrong D. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009 Jul;161(1):1-7.

Toplam 20 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	Türkçe
Bölüm	Araştırma Makalesi
Yazarlar	Efsun Tanacan 0000-0003-1975-7460 Nermin Karaosmanoğlu Engin Karaaslan Bu kişi benim Hatice Meral Ekşioğlu Bu kişi benim
Yayımlanma Tarihi	29 Ağustos 2018
Gönderilme Tarihi	25 Ekim 2018
Yayımlandığı Sayı	Yıl 2018 Cilt: 51 Sayı: 2

Kaynak Göster

AMA	Tanacan E, Karaosmanoğlu N, Karaaslan E, Ekşioğlu HM. PSORİYAZİS VULGARİSİN ŞİDDETİ, VÜCUT KİTLE İNDEKSİ VE BEL ÇEVRESİ ARASINDAKİ İLİŞKİNİN DEĞERLENDİRİLMESİ. Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi. Ağustos 2018;51(2):150-153.